1. Medtech Insight
  2. >>Archive

A Decade of Development for SMSI: Will it lead to Improved Accuracy in CGM?

The mission of ten-year old company Sensors for Medicine & Science is to develop a sensor that would obviate the need for patients with diabetes to extract blood or fluid samples for testing. Implanted under the skin, the SMSI sensor is continuously immersed in interstitial fluid containing glucose and provides frequent glucose readings. It thus has the potential to become the cornerstone of a new continuous glucose monitoring (CGM) system, one that works very differently than the early-generation systems on the market today. Part of a group of articles that includes: "Where are They Now? Checking in on Three Glucose Monitoring Companies," "Pelikan Swoops in on the Big Four" and "GlucoLight: Making Non-Invasive Glucose Monitoring Real."

In the medical device industry, products that undergo years of development can face the risk of being obsolete before they ever see the light of day. Device companies have succumbed to that pitfall in heart failure, where complex artificial hearts and ventricular assist devices that didn’t make it to the market after decades of research are already being supplanted by much simpler partial support devices, and in coronary artery disease, where stents killed coronary-artery-clearing tools. Technologies change at a rapid pace, but so also does clinical practice as the understanding of disease processes evolves. Fortunately for Sensors for Medicine & Science Inc. (SMSI), the field of diabetes moved exactly in the direction that the company was headed when it was founded in 1997. Ten years later, the company now finds that its technology is perfectly positioned to ride the newest wave in diabetes care, continuous glucose monitoring.

We first wrote about SMSI in 1998, a promising time in the field of glucose testing. (See "Sensors for Medicine and Science Inc." IN VIVO, May 1998 Also see "Sensors for Medicine and Science Inc." - In Vivo, 1 May, 1998..) Not long before, Abbott Laboratories Inc. had acquired MediSense for $876 million, a price that represented a 50% premium

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.